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Abstract
Background Understanding emergency department and healthcare utilisation related to acute recreational drug toxicity (ARDT)
generally relies on nationally collated data based on ICD-10 coding. Previous UK studies have shown this poorly captures the
true ARDT burden. The aim of this study was to investigate whether this is also the case elsewhere in Europe.
Methods The Euro-DEN Plus database was interrogated for all presentations 1st July to 31st December 2015 to the EDs in (i) St
Thomas’Hospital, London, UK; (ii) Universitätsspital Basel, Basel, Switzerland; and (iii) Zealand University Hospital, Roskilde,
Denmark. Comparison of the drug(s) involved in the presentation with the ICD-10 codes applied to those presentations was
undertaken to determine the proportion of cases where the primary/subsequent ICD-10 code(s) were ARDT related.
Results There were 619 presentations over the 6-month period. Two hundred thirteen (34.4%) of those presentations were coded;
89.7% had a primary/subsequent ARDT-related ICD-10 code. One hundred percent of presentations to Roskilde had a primary
ARDT ICD-10 code compared to 9.6% and 18.9% in Basel and London respectively. Overall, only 8.5% of the coded presen-
tations had codes that captured all of the drugs that were involved in that presentation.
Conclusions While themajority of primary and secondary codes applied related to ARDT, often they did not identify the actual drug(s)
involved. This was due to both inconsistencies in the ICD‐10 codes applied and lack of ICD‐10 codes for the drugs/NPS. Further
work and education is needed to improve consistency of use of current ICD‐10 and future potential ICD‐11 coding systems.
Keywords Recreational drugs . Novel psychoactive substances . Acute toxicity . Clinical coding . Emergency department
Introduction
The International Classification of Disease version 10 (ICD-
10) system is often used to code hospital outpatient atten-
dances, emergency department (ED) attendances and hospital
discharges and used to understand the burden on healthcare
systems related to specific diseases/medical conditions [1].
The Hospital Episode Statistics (HES) in the UK collate over
125 million ICD-10 coded episodes per year and HES data is
used to demonstrate the prevalence of different medical con-
ditions across the UK, as well as for planning and funding
health service provision [1].
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Although ICD-10 coding can generate representative data for
routine surgical admissions to hospital and for general medical
conditions (for example, cancer and heart disease), previous UK
studies have shown it is less robust at capturing recreational drug-
related burden of health care utilisation [2, 3]. There are a number
of reasons that potentially explain this. First, in many countries
in Europe, ICD-10 codes are usually only applied to patients
admitted to hospital beyond the ED, based on local country
coding mechanisms. Over three quarters of acute recreational
drug toxicity (ARDT) patients are discharged directly from the
ED, and since they are not admitted to hospital, they are not
captured by the ICD-10 coding system [4]. ED presentations
not admitted to hospital may be coded at a Bhigh level^ of ICD-
10 codes, rather than by the detailed sub-classifications of ICD-
10 codes leading to less granularity of coding for the episode
[1–3]. Second, many established recreational drugs (e.g.
MDMA, ketamine) lack formal ICD-10 codes and therefore cod-
ing of those substances specifically is not possible. Similarly, the
rapidly emerging number of new psychoactive substances (NPS)
is also not codeable under existing ICD-10 codes [1–3]. Finally,
national coding collation systems, such as HES, typically report
on primary ICD-10 diagnostic code, and even where codes do
exist, the primary diagnostic code applied to an admission may
reflect the condition caused by the recreational drug rather than
the recreational drug used. For example, cocaine-related myocar-
dial infarction may have a primary code of myocardial infarction
with cocaine coded as a secondary or subsequent diagnostic
code. Using only the primary ICD-10 code will mean the recre-
ational drug involvement will not be captured.
Therefore, nationally collated ICD-10 coded data in the UK
means that the true burdenofARDT-related health care utilisation
is not understood [1–6]. However, there have been no studies to
determinewhether these issues are only representative of theUK,
or whether this also occurs in other European healthcare systems.
In this study,we have utilised knownEDpresentationswith acute
recreational drug andNPS toxicity reported to theEuropeanDrug
Emergencies Network Plus (Euro-DEN Plus) project from three
cities in three different European countries (Denmark, Switzerland,
and the UK) to further understand the issues of using ICD-10
coded data to capture the healthcare burden related to their use
and we sought to determine if there is concordance between
ICD-10 coding and Euro-DEN Plus case coding of recreational
drugs and NPS used in three distinct European medical centres.
Methods
The development of the initial Euro-DEN project and the local
approval processes have been previously described [4, 7].
Briefly, the initial Euro-DEN project and the subsequent Euro-
DEN Plus projects collect the following data from routine med-
ical notes of all patients presenting with acute recreational drug
(including NPS) toxicity: patient demographics, drug(s) used,
clinical features associated with the presentation and physiolog-
ical observations on presentation, treatment(s) given, disposition
from ED (and overall survival to discharge), and length of stay
[4, 7, 8]. Each Euro-DEN Plus centre is responsible for ensuring
all relevant cases are identified and entered into the project data-
base. The Euro-DEN Plus database was interrogated to identify
all presentations between 1st July 2015 and 31st December 2015
to the three Euro-DEN Plus centres participating in this study: (i)
St Thomas’Hospital, London,UK; (ii) theUniversityHospital of
Basel (Universitätsspital Basel), Basel, Switzerland; and (iii)
Zealand University Hospital, Roskilde, Denmark. For each pre-
sentation, the reported drug(s) used were extracted. All of these
hospitals are urban hospitals co-located with universities and act
both as secondary care providers for their local residents and are
tertiary referral centres for specialist care.
The central hospital coding departments at participating hos-
pitals were asked in the first quarter of 2017whether any ICD-10
codes had been applied to each presentation and what codes had
been applied in order of coding (primary, secondary and subse-
quent codes). The coding had been undertaken part of routine
clinical care in each hospital at the time of the presentation. Those
undertaking the coding were not aware of this future study.
Analysis was undertaken to determine (i) the proportion of
cases where there were no diagnostic codes recorded at all, (ii)
the proportion of cases where the primary diagnostic codes in-
cluded an ARDT-related code (defined as one of the following
ICD-10 codes: F11–F19, T40–43, T50, T59 or T65), (iii) the
proportion of cases where a second and/or subsequent ARDT-
related code was recorded (defined as one of the following ICD-
10 codes: F11–F19, T40–43, T50, T59 or T65 along with X40,
X41, X42, X44, X47, X61, X62, X64 and Z27.2), and (iv) the
most common types of primary coding recorded for those pre-
sentations where no code related to ARDT was recorded. In
addition, analysis was undertaken to determine whether ICD-
10 codes related to the drug category(ies) used (defined as stim-
ulants, cannabinoids, hallucinogens and depressants). Finally,
sub-analysis comparing the concordance of drugs reported in
the Euro-DEN Plus cases to the ICD-10-coded drugs was under-
taken for the opioids, cannabinoids, cocaine, and mephedrone.
These drugs were chosen due to the frequency of use, concerns
about harms related to their use and/or that there have specific
codes in the ICD-10 coding system that identify them.
Statistical Analysis
Descriptive statistics, undertaken using Excel 2013, were used to
describe theproportionof cases ineachgroupduringanyanalysis.
Results
During the 6-month study period, there were a total of
619 ARDT-related presentations to the three participating
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Euro-DEN Plus centres (London, 450; Basel, 115;
Roskilde, 54). Of these presentations, 213 (34.4%) had
one or more ICD-10 codes applied to that presentation,
with variability between the centres: Basel, 14.8%;
London, 31.6% and Roskilde, 100% (Fig. 1). Four hun-
dred six (71.9%) of London and Basel presentations did
not have any ICD-10 codes applied; in 365 (89.9% of
uncoded episodes), the patient was not admitted beyond
the ED (Basel, 95; London, 270): (i) medically discharged
302 (219 London; 83 Basel), (ii) self-discharged and/or
did not wait 62 (50 London; 12 Basel) or (iii) died in
the ED 1 (London).
ICD-10 Clinical Coding
Of the 213 coded presentations, 191 (89.7% of coded
presentations) had either a primary, secondary and/or sub-
sequent ARDT (ARDT) code. Twenty-two coded presen-
tations had no ARDT-related ICD-10 codes applied; all of
these were in London.
Primary Clinical Code
One hundred fifty of the presentations (24.2% of all presenta-
tions, 70.4% of coded presentations) had a primary ARDT
All Euro-DEN Plus 
Presentaons
619
ICD-10 coded 
presentaons
213 (34.4%)
ARDT-coded 
presentaons
191 (30.9%)
Presentaons with 
primary ARDT code
150 (24.2%)
Presentaons with 
secondary or 
subsequent ARDT code
41 (6.6%)Non-ARDT-coded 
presentaons
22 (10.3%)
Non-coded 
presentaons
406 (65.6%)
Basel Euro-DEN Plus 
presentaons
115
ICD-10 coded 
presentaons
17 (14.8%)
ARDT-coded 
presentaons
17 (14.8%)
Presentaons with 
primary ARDT code
11 (9.6%)
Presentaons with 
secondary or 
subsequent ARDT code
6 (5.2%)Non-ARDT-coded 
presentaons
0 (0%)
Non-coded 
presentaons
98 (85.2%)
London Euro-DEN Plus 
presentaons
450
ICD-10 coded 
presentaons
142 (31.6%)
ARDT-coded 
presentaons
120 (26.7%)
Presentaons with 
primary ARDT code
85 (18.9%)
Presentaons with 
secondary or 
subsequent ARDT code
35 (7.8%)Non-ARDT-coded 
presentaons
22 (4.9%)
Non-coded 
presentaons
308 (68.4%)
Roskilde Euro-DEN Plus 
presentaons
54
ICD-10 coded 
presentaons
54 (100%)
ARDT-coded 
presentaons
54 (100%)
Presentaons with 
primary ARDT code
54 (100%)
Presentaons with 
secondary or 
subsequent ARDT code
0 (0.0%)Non-ARDT-coded 
presentaons
0 (0.0%)
Non-coded 
presentaons
0 (0.0%)
Fig. 1 Summary of coding and
application of acute recreational
drug-related ICD-10 codes for all
cases and by centre involved in
the study
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ICD-10 code. All of the Roskilde presentations had a primary
ARDT code, compared to 11 (9.6% of total presentations) in
Basel and 85 (18.9%) in London (Fig. 1). Overall, there were
27 different primary ICD-10 codes applied, of which 7 (71
presentations) related to Bmental and behavioural disorders^
group of codes (F codes) and 20 (79 presentations) related to
Bpoisoning/toxic effects^ group of codes (T codes) (Table 1).
The 63 presentations without a primary ARDT-related ICD-10
code had 36 different primary ICD-10 codes applied (Table 2);
the most commonly used codes related to: (i) alcohol (15
presentations), (ii) mental health (15 presentations) and (iii)
head injury (5 presentations). Of the 15 coded with an alcohol-
related ICD-10 code, all had recorded whether alcohol had
either been used (13 (86.7%)) or not used (2 (13.3%)).
Secondary or Subsequent Clinical Codes
A further 41 presentations (6.6% of all presentations, 19.2%
of coded presentations) would be identified as a recreational
drug-related acute toxicity presentation from a secondary or
subsequent ICD-10 ARDT codes. There were 31 different
ICD-10 codes applied as secondary/subsequent codes, of
which 8 related to the Bmental and behavioural disorders^
group of codes (F codes), 14 related to Bpoisoning/toxic
effects^ group of codes (T codes), 9 related to the Bexternal
causes of morbidity andmortality^ and/or Bfactors influencing
health status^ groups of codes (X and Z codes) (Table 1).
Concordance of Euro-DEN Plus Drugs Identified
and Drugs Identified by ICD-10 Clinical Codes
Of the 213 ICD-10-coded presentations, only 18 (8.5%) had
ICD-10 codes applied which captured all of the recreational
drug(s) that were involved in an individual Euro-DEN Plus
presentation (for example, if they had used cannabis and co-
caine and ICD-10 codes for cannabis and cocaine had been
applied), ranging from 0.7 in London to 29.6% in Roskilde
(Table 3); in addition, a further 33 (15.5%) presentations had
ICD-10 codes which captured at least one but not all of the
drug(s) that had been reported in that individual presentation
(for example, if they had used cannabis and cocaine but only
an ICD-10 code for cannabis had been applied). This meant
that a total of 162 (76.1%) presentations had ICD-10 codes for
drug(s) other than those that had been recorded for that pre-
sentation in the Euro-DEN Plus database (for example, a pa-
tient who had used cannabis and cocaine but an ICD-10 code
for heroin only was applied).
The accuracy of ICD-10 coding and the detection of pre-
sentations by searching applied ICD-10 codes for opioids,
cannabinoids, cocaine and the NPS mephedrone is
summarised below.
Opioids
& Twenty-five presentations had a primary opioid toxicity-
related ICD-10 code (F11: mental and behaviour disorders
due to use of opioids or T40.1, T40.2, T40.3: poisoning by
heroin, other opioids or methadone respectively): 12
(48.0%) had reported use of an opioid.
& Ninety-six Euro-DEN Plus presentations included the use
of an opioid: 8 (8.3%) would be identified by searching
primary ICD-10 codes and 14 (14.6%) by subsequent
ICD-10 codes equating to an overall detection rate of
22.9%.
Cocaine
& Nineteen presentations had a primary cocaine toxicity-
related ICD-10 code (F14: mental and behaviour disorders
due to use of cocaine or T40.5: poisoning by cocaine): 16
(84.2%) had reported use of cocaine.
& One hundred forty-nine Euro-DEN Plus presentations in-
cluded the use of cocaine: 17 (11.4%) would be identified
by searching primary ICD-10 codes and 12 (8.1%) by
subsequent ICD-10 codes equating to an overall detection
rate of 19.5%.
Cannabis and Synthetic Cannabinoids
& Seventeen presentations had a primary cannabinoid-
related ICD-10 code (F12: mental and behaviour disorders
due to use of cannabinoids or T40.7: poisoning by canna-
bis): 15 (88.2%) had reported use of cannabis and/or syn-
thetic cannabinoids.
& One hundred sixteen Euro-DEN Plus presentations in-
cluded the use of cannabis and/or synthetic cannabinoids:
15 (12.9%) would be identified by searching primary
ICD-10 codes and 6 (5.2%) by subsequent ICD-10 codes
equating to an overall detection rate of 18.1%.
Mephedrone
& There are no ICD-10 codes that relate directly to
mephedrone.
& Forty-six Euro-DEN Plus presentations had used
mephedrone: none would be identified directly by
searching primary or subsequent ICD-10 codes. Twenty-
one mephedrone presentations were coded: 12 (57.1%)
had primary ICD-10 codes that were toxicity/poisoning
ICD-10 codes (poisoning by non-specific stimulants (5),
cocaine (2), general anaesthetics (2), alcohol (1), metha-
done (1) and cannabis (1)).
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Table 1 Frequency of specific primary (150 presentations) and subsequent (41 presentations) ICD-10 diagnostic codes related to acute recreational
drug toxicity (N/A - not applicable as X codes relate to intention of exposure and cannot be primary ICD-10 code applied)
ICD-10
code
Descriptive ICD-10 code Primary
code
Secondary/
subsequent
(n) (n)
F11 Mental and behavioural disorders due to use of opioids 13 17
F12 Mental and behavioural disorders due to use of cannabinoids 13 12
F13 Mental and behavioural disorders due to use of sedatives or hypnotics 5 18
F14 Mental and behavioural disorders due to use of cocaine 9 23
F15 Mental and behavioural disorders due to use of other stimulants 12 27
F16 Mental and behavioural disorders due to use of hallucinogens 3 0
F17 Mental and behavioural disorders due to use of tobacco 0 19
F18 Mental and behavioural disorders due to use of volatile solvents 0 1
F19 Mental and behavioural disorders due to multiple drug use of other psychoactive substances 16 6
T40 Poisoning by narcotics and psychodysleptics (hallucinogens)
T40.1 Heroin 6 4
T40.2 Other opioids 1 1
T40.3 Methadone 5 2
T40.4 Other synthetic narcotics 1 0
T40.5 Cocaine 10 3
T40.6 Other and unspecified narcotics 5 0
T40.7 Cannabis 4 2
T40.8 Lysergide (LSD) 2 0
T40.9 Other and unspecified psychodysleptics (hallucinogens) 2 0
T41 Poisoning by anaesthetics and therapeutic gases
T41.0 Intravenous anaesthetics 1 0
T41.2 Other and unspecified general anaesthetics 9 2
T42 Poisoning by antiepileptic, sedative-hypnotic and antiparkinsonism drugs
T42.4 Benzodiazepines 1 3
T42.6 Other antiepileptic and sedative-hypnotic drugs 1 1
T43 Poisoning by psychotropic drugs, not elsewhere classified
T43.0 Tricyclic and tetracyclic antidepressants 1 0
T43.2 Other and unspecified antidepressants 0 1
T43.5 Other and unspecified antipsychotics and neuroleptics 2 0
T43.6 Psychostimulants with abuse potential (excl. cocaine) 17 7
T43.8 Other psychotropic drugs, not elsewhere specified 5 1
T46 Poisoning by agents primarily affecting the cardiovascular system
T46.3 Coronary vasodilators, not elsewhere classified 0 1
T46.7 Peripheral vasodilators 0 1
T50 Poisoning by diuretics and other and unspecified drugs, medicaments and biological substances
T50.9 Poisoning: other and unspecified drugs, medicaments and biological substances 4 0
T59 Toxic effect of other gases, fumes and vapours
T59.8 Other specified gases, fumes and vapours 1 0
T65 Toxic effect of other and unspecified substances
T65.9 Toxic effect of unspecified substance 1 0
T88.7 Unspecified adverse effect of drug or medicament 0 1
X40 Accidental poisoning by and exposure to nonopioid analgesics, antipyretics and antirheumatics N/A 1
X41 Accidental poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and
psychotropic drugs, not elsewhere classified
N/A 19
X42 Accidental poisoning by and exposure to narcotics and psychodysleptics (hallucinogens),
not elsewhere specified
N/A 16
X44 N/A 15
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Discussion
Approximately one third of European Drug Emergencies
Network (Euro-DEN) Plus presentations to the EDs in the
three cities (London, UK; Roskilde, Denmark and Basel,
Switzerland) were coded using the ICD-10 coding systems,
although there was variability in the proportion that were cod-
ed by centre. This study has demonstrated that the majority of
primary and secondary codes applied related to acute recrea-
tional drug toxicity, but often they were not specific to the
drug(s) used. The concordance of ICD-10 coding with drugs
used showed high specificity but low sensitivity: those pre-
sentations coded with a specific drug ICD-10 code were likely
to have taken that drug but the majority who had used the drug
were not likely to be have the relevant ICD-10 code applied.
Previous studies have shown that around 50% of presenta-
tions with ARDT are discharged directly from the ED, and
these presentations are unlikely to be coded using the ICD-
10 coding system as this relates to patients admitted to hospital
[2, 3]. In this study, in the two centres (Basel and London)
with more uncoded Euro-DEN Plus presentations, nearly 90%
of these had only been managed within the ED, consistent
with those previously reported studies [4]. However, in
Roskilde, Denmark, all of the presentations were coded as
there is a requirement for all hospital presentations to be coded
and reported to the National Register (Landspatientregisteret).
Use of ICD-10 data in Denmark would potentially capture the
burden of number of presentations; it would not allow true
understanding of the burden for an individual drug, since the
codes applied were not necessarily accurate for the drug(s)
used. Further work is needed to understand whether other
European countries utilise different methods for coding emer-
gency presentations to see whether this variability in the cap-
ture of recreational drug presentations is replicated elsewhere.
Of the primary ICD-10 codes applied to the Euro-DEN
Plus presentations, around 70% could be classified as a code
that related to either the mental and behavioural or poisoning/
toxicological effects of a recreational drug. Of the 213
presentations where a primary diagnostic code was recorded,
only 150 (70.4%) received a primary ICD-10 diagnostic code
that was related to ARDT. Some of the Bacute drug toxicity^-
related ICD-10 codes applied may not at initial review be
consistent with the use of a recreational drug. One example
is those presentations that had a primary ICD-10 code related
to poisoning by anaesthetics agents; it is possible that some of
these presentations related to the acute toxicity from either
GBL/GHB or ketamine use since both GHB and ketamine
have been used as anaesthetics and there is no specific ICD-
10 code for these drugs. In a previous study, where clinical
coders coded simulated ARDT presentations, the ICD-10 di-
agnostic code BT41.2 Poisoning by other and unspecified gen-
eral anaesthetics^ was used by 14% for a GBL-related col-
lapse in a sauna [3]. The non-ARDT primary ICD-10 codes
applied related to a range of other medical conditions, which
could be considered as caused by the use of a recreational
drugs/NPS such as acute mental health or neuropsychiatric
disorders, cardiac toxicity or trauma. It is also interesting to
note that the majority intent-related ICD-10 codes applied
related to accidental rather than intentional poisoning. It is
unknown whether coders used accidental codes as individuals
are unlikely to use them with an intent to overdose, even if
there is intentional use of a substance that could be associated
with the risk of acute toxicity when used.
The main issue identified with this study is likely under de-
tection of presentations through the utilisation of searching by
ICD-10 codes. In a previous retrospective review of 484 known
acute recreational toxicity presentations to an ED in London,
UK, only 13% had been coded with a primary ICD-10 code that
related to ARDT and overall looking at levels of coding, only
approximately 20% of presentations had one or more ICD-10
codes applied that could relate to ARDT [2]. There was high
specificity to detect specific drugs, since when an ICD-10 code
was applied to a presentation, the majority of those presentations
involved the use of that drug. However, there was low sensitivity
since the majority of those who had actually used a specific drug
did not have the relevant drug-specific ICD-10 code applied to
Table 1 (continued)
ICD-10
code
Descriptive ICD-10 code Primary
code
Secondary/
subsequent
(n) (n)
Accidental poisoning by and exposure to other and unspecified drugs, medicaments and biological
substances
X47 Accidental poisoning by and exposure to other gases and vapours N/A 1
X61 Intentional self-poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism
and psychotropic drugs, not elsewhere specified
N/A 9
X62 Intentional self-poisoning by and exposure to narcotics and psychodysleptics (hallucinogens),
not elsewhere classified
N/A 7
X64 Intentional self-poisoning by and exposure to other and unspecified drugs, medicaments and
biological substances
N/A 6
Z72.2 Drug use 0 1
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the presentation. NPS will not have specific ICD-10 codes, since
they have not been used for as long as the current ICD codes
have been. Mephedrone was the most widely used and available
NPS at the time of these Euro-DEN Plus presentations; since
there is no ICD-10 code for mephedrone, it is not possible to
look at coded presentations to detect mephedrone use. In part,
Table 2 Primary ICD-10
diagnostic codes not related to
acute recreational drug toxicity
ICD-10 code Descriptive ICD-10 code Cases applied to
(n)
Metabolic/endocrine (6 presentations)
D74.9 Methaemoglobinaemia, unspecified 2
E78.1 Pure hyperglyceridaemia 1
E87.2 Acidosis 1
T38.8 Other and unspecified hormones and their synthetic substitutes 1
N17.9 Acute renal failure, unspecified 1
Alcohol related (15 presentations)
F10.0 Mental and behavioural disorders due to use of alcohol 11
F10.3 Mental and behavioural disorders due to use of alcohol (withdrawal state) 3
T51.0 Ethanol 1
Neuropsychiatric (21 presentations)
F22.0 Delusional disorder 1
F29 Unspecified nonorganic psychosis 2
F41.0 Panic disorder (episodic paroxysmal anxiety) 3
F41.9 Anxiety disorder, unspecified 2
G40.2 Localization-related (focal) (partial) symptomatic epilepsy and epileptic
syndromes with complex partial seizures
1
G41.0 Grand mal status epilepticus 1
G93.6 Cerebral oedema 1
R45.2 Unhappiness 1
R45.8 Other symptoms and signs involving emotional state (suicidal ideation
(tendencies))
6
R55 Syncope and collapse 3
Cardiorespiratory (8 presentations)
I26.9 Pulmonary embolism without mention of acute cor pulmonale 1
I46.0 Cardiac arrest with successful resuscitation 1
J14 Pneumonia due to Haemophilus influenzae 1
J69.0 Pneumonitis due to food and vomit 2
R06.8 Other and unspecified abnormalities of breathing 1
R07.4 Chest pain unspecified 2
Gastrointestinal (3 presentations)
K92.2 Gastrointestinal haemorrhage unspecified 1
R10.4 Other and unspecified abdominal pain 1
R11 Nausea and vomiting 1
Trauma/injury related (8 presentations)
S00.7 Multiple superficial injuries of the head 1
S00.8 Superficial injury of other parts of the head 1
S01.0 Open wound of scalp 1
S01.1 Open wound of eyelid and periocular area 1
S09.9 Unspecified injury of the head 2
T00.8 Superficial injuries involving other combinations of body regions 1
T14.2 Fracture of unspecified body region 1
Other (2 presentations)
M46.4 Discitis, unspecified 1
M54.2 Cervicalgia 1
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this is due to ICD-10 having been endorsed for use by theWorld
Health Organisation, prior to widespread use of NPS. However,
when we look at the known mephedrone presentations, only
around a third had an ICD-10 code applied that related to the
use of a stimulant recreational drug (which would be the most
appropriate for mephedrone in the absence of a specific ICD-10
code). This is different to the previous clinical coding study of
simulated ARDT presentations, where around 68% applied a
primary ICD-10 code of Bpoisoning by psychostimulants with
abuse potential^ to a patient with anxiety and palpitations after
the use of mephedrone [3]. There have been no changes to the
coding practice in the study centres since the cases used in this
study, and therefore we would not expect there to have been any
improvement in quality of local coding. However, following this
study, the proposed ICD-11 coding system was released on the
18th June 2018 [9]. The proposed ICD-11 coding system appears
to have incorporated more coding categories related to the use of
recreational drugs and novel psychoactive substances, including
proposed specific codes for the synthetic cathinones, MDMA
and related drugs and the synthetic cannabinoids. These changes
may in part help with some of the coding issues that we have
identified in this and previous studies, enabling better under-
standing of the burden of health care utilisation related to the
use of a wider range of substances. However, despite the release
of the proposed ICD-11 coding system, the expectation is that
this will be endorsed by the 72nd World Health Assembly in
May 2019 and therefore it is unlikely to be used in routine coding
reporting until 2022 onwards.
The European Monitoring Centre for Drugs and Drug
Addiction (EMCDDA) through its REITOX national focal point
network early warning system collates information on the prev-
alence of use and harms associated with the use of both classical
recreational drugs and novel psychoactive substances [10]. A
survey of these national focal points has demonstrated only ~
50% of countries had any systematic data collection system in
place to detect the acute harms of classical recreational drugs and
novel psychoactive substances [11]. Those that did largely relied
on information from poison information centres and/or data from
ICD-10/other clinical coding systems, with limitations on the
detail of information provided or the accuracy of detection of
cases. The Euro-DEN Plus project enables a detailed data collec-
tion currently, in May 2018, within 31 hospitals in 21 European
and neighbouring countries, which can provide detailed
information to the EMCDDA on recreational drugs/NPS associ-
ated with acute toxicity and describe the pattern of acute toxicity
seen with different drugs/NPS [4, 8, 12–14]. As such data from
the Euro-DEN Plus project now forms part of the annual
EMCDDA European Drug Report, adding the existing key indi-
cators around drug detection, drug-related deaths and use of
treatment services for drug dependency [15–17]. In the USA,
The Toxicology Investigators Consortium (ToxIC) project col-
lects data on cases directly reviewed by medical/clinical toxicol-
ogists from a number of hospitals across the USA [18–21]. This
has some similarities to the Euro-DEN Plus project, in that a
proportion of the cases in the Euro-DEN Plus project have been
seen by amedical/clinical toxicologist during their hospital atten-
dance. However, the Euro-DEN Plus project has the advantage
of collecting all cases presenting to each individual participating
centre irrespective of whether they have been seen at the
bedside by a medica or clinical toxicologist. This means cases
presenting outside of the time that a medical/clinical toxicologist
is on site will also be captured. Additionally, it captures poten-
tially less severe cases who may be discharged directly by the
emergency department physicians, rather than needing to involve
a medical/clinical toxicologist.
The main limitation of the Euro-DEN Plus dataset is that
drug(s) used is based on self-report or clinicians’ interpreta-
tion of the presentation for the majority of the cases. The use
of self-reported and/or clinical interpretation of drugs involved
reflects real-life clinical practice in many hospitals, where the
majority of patients do not have analytical confirmation un-
dertaken. A previous sub-group analysis of Euro-DEN Plus
presentations with analytical confirmation of drugs used
showed there was good correlation between self-reported
use of drugs such as heroin, methadone, cocaine, and amphet-
amines [22]. There was less correlation between cases of NPS-
related toxicity, as NPS cannot be detected with the usual drug
screening immunoassays, and some substances were not rou-
tinely screened for due to limited detection windows in bio-
logical matrices (e.g. volatile nitrites and GHB/GBL).
Conclusion
Currently, the main issue in understanding the burden of acute
healthcare utilisation related to the use of recreational drugs
Table 3 Concordance of ICD-10
codes with drugs captured in each
presentation by Euro-DEN by site
Basel London Roskilde Combined
No. % No. % No. % No. %
ICD-10-coded presentations 17 142 54 213
All drugs captured by Euro-DEN 1 5.9 1 0.7 16 29.6 18 8.5
At least one drug captured by Euro-DEN 6 35.3 26 18.3 19 35.2 51 23.9
No drugs captured by Euro-DEN 11 64.7 116 81.7 35 64.8 162 76.1
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and NPS is the lack of easily available locally, regionally, or
nationally aggregate data on ED presentations. This is due to
the majority of presentations not being coded, inconsistencies
in the ICD-10 codes applied to presentations, and lack of ICD-
10 codes for the drugs/NPS used. While there are plans to
adapt the current ICD coding system [9], further work to de-
velop more automated and easily implementable systems
would enable more rapid and complete capture on the acute
health burdens associated with drugs and NPS. This would
then allow legislative, public health bodies, and emergency/
treatment services to understand the overall burden at a na-
tional level and regional differences to enable more appropri-
ately targeted treatment service provision and public health
interventions to reduce the harms associated with their use.
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